Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to investigate the effectiveness of otenaproxesul in acute pain

Next Previous
Trial Profile

A study to investigate the effectiveness of otenaproxesul in acute pain

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Otenaproxesul (Primary)
  • Indications Acute pain
  • Focus Adverse reactions
  • Sponsors Antibe Therapeutics

Most Recent Events

  • 08 Apr 2024 According to an Antibe Therapeutics media release, company will seek a further extension of the Stay Period in order to be able to continue engaging with the U.S. Food and Drug Administration with respect to the previously announced hold on the Company's planned Phase II trial and to determine the appropriate next steps.
  • 08 Apr 2024 According to an Antibe Therapeutics media release, company will seek a further extension of the Stay Period in order to be able to continue engaging with the U.S. Food and Drug Administration with respect to the previously announced hold on the Company's planned Phase II trial and to determine the appropriate next steps.
  • 01 Apr 2024 According to an Antibe Therapeutics media release, company announced that it received verbal notice on March 28, 2024 from the U.S. Food and Drug Administration (FDA) that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial. Antibe expects to receive a formal Clinical Hold Letter from the FDA within 30 days outlining their rationale and further details.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top